{"id":67402,"date":"2026-06-05T13:15:44","date_gmt":"2026-06-05T05:15:44","guid":{"rendered":"https:\/\/flcube.com\/?p=67402"},"modified":"2026-06-05T13:15:45","modified_gmt":"2026-06-05T05:15:45","slug":"innovent-biologics-reports-positive-phase-iii-results-for-ibi343-in-advanced-gastric-cancer-cldn18-2-targeting-adc-files-nda-with-nmpa","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=67402","title":{"rendered":"Innovent Biologics Reports Positive Phase III Results for IBI343 in Advanced Gastric Cancer \u2013 CLDN18.2-Targeting ADC Files NDA with NMPA"},"content":{"rendered":"\n<p class=\"wp-block-paragraph\"><strong>Innovent Biologics<\/strong> (<a href=\"https:\/\/www.google.com\/finance\/quote\/1801:HKG\">HKG: 1801<\/a>) announced that the pre-specified first interim analysis from the global <strong>Phase III G-HOPE-001 study<\/strong> (NCT06238843) of <strong>IBI343<\/strong> in patients with <strong>advanced gastric cancer<\/strong> has <strong>met its primary endpoint per protocol<\/strong>, demonstrating <strong>superior efficacy<\/strong> and a <strong>favorable safety and tolerability profile<\/strong>.<\/p>\n\n\n\n<h2 id=\"h-clinical-trial-milestone\" class=\"wp-block-heading\">Clinical Trial Milestone<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Item<\/th><th>Detail<\/th><\/tr><\/thead><tbody><tr><td><strong>Study<\/strong><\/td><td>G-HOPE-001 (NCT06238843) \u2013 Global Phase III<\/td><\/tr><tr><td><strong>Patient Population<\/strong><\/td><td>Advanced gastric cancer<\/td><\/tr><tr><td><strong>Analysis<\/strong><\/td><td>Pre-specified first interim analysis<\/td><\/tr><tr><td><strong>Primary Endpoint<\/strong><\/td><td>Met per protocol<\/td><\/tr><tr><td><strong>Efficacy<\/strong><\/td><td>Superior compared to control arm<\/td><\/tr><tr><td><strong>Safety Profile<\/strong><\/td><td>Favorable with good tolerability<\/td><\/tr><tr><td><strong>Regulatory Action<\/strong><\/td><td>New Drug Application (NDA) filed with China&#8217;s NMPA<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 id=\"h-drug-profile-amp-mechanism-of-action\" class=\"wp-block-heading\">Drug Profile &amp; Mechanism of Action<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Molecule:<\/strong> IBI343 \u2013 <strong>biomarker-directed, CLDN18.2-targeting antibody-drug conjugate (ADC)<\/strong><\/li>\n\n\n\n<li><strong>Target:<\/strong> CLDN18.2-positive tumors across multiple cancer types<\/li>\n\n\n\n<li><strong>Payload:<\/strong> <strong>Exatecan<\/strong> \u2013 highly potent topoisomerase I inhibitor<\/li>\n\n\n\n<li><strong>Linker Technology:<\/strong> <strong>Cleavable linker<\/strong> enabling selective payload delivery to tumor cells<\/li>\n\n\n\n<li><strong>Engineering Innovation:<\/strong> <strong>Fc-silent design<\/strong> to minimize off-target toxicity outside tumor tissue<\/li>\n\n\n\n<li><strong>Therapeutic Approach:<\/strong> Precision therapy specifically designed for CLDN18.2-positive tumor populations<\/li>\n<\/ul>\n\n\n\n<h2 id=\"h-clinical-significance-amp-market-opportunity\" class=\"wp-block-heading\">Clinical Significance &amp; Market Opportunity<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Aspect<\/th><th>Impact<\/th><\/tr><\/thead><tbody><tr><td><strong>Gastric Cancer Burden<\/strong><\/td><td>China accounts for approximately 40% of global gastric cancer cases, with limited effective treatment options for advanced disease<\/td><\/tr><tr><td><strong>CLDN18.2 Expression<\/strong><\/td><td>Present in 30-40% of gastric cancers, representing a substantial biomarker-defined patient population<\/td><\/tr><tr><td><strong>Competitive Landscape<\/strong><\/td><td>First CLDN18.2-targeting ADC to demonstrate positive Phase III results in gastric cancer<\/td><\/tr><tr><td><strong>Regulatory Pathway<\/strong><\/td><td>NDA filing positions IBI343 for potential accelerated approval in China, with global regulatory discussions planned<\/td><\/tr><tr><td><strong>Commercial Potential<\/strong><\/td><td>Peak annual sales projected at $500-800 million globally, with China representing 50-60% of initial market<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 id=\"h-strategic-implications-for-innovent\" class=\"wp-block-heading\">Strategic Implications for Innovent<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Pipeline Validation:<\/strong> Success validates Innovent&#8217;s ADC platform capabilities and biomarker-driven development strategy<\/li>\n\n\n\n<li><strong>Commercial Infrastructure:<\/strong> Leverages existing oncology commercial team and hospital relationships across China<\/li>\n\n\n\n<li><strong>Global Expansion:<\/strong> Positive data supports planned regulatory filings in US, EU, and other major markets<\/li>\n\n\n\n<li><strong>Combination Potential:<\/strong> Opens opportunities for combination studies with checkpoint inhibitors and other targeted therapies<\/li>\n\n\n\n<li><strong>Platform Extension:<\/strong> CLDN18.2 targeting approach may be applicable to other tumor types including pancreatic and esophageal cancers<\/li>\n<\/ul>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Forward\u2011Looking Statements<\/strong><br>This brief contains forward\u2011looking statements regarding clinical trial results, regulatory submissions, and commercial expectations for IBI343. Actual results may differ due to risks including final regulatory decisions, competitive developments, and market dynamics.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n\n\n\n<div data-wp-interactive=\"core\/file\" class=\"wp-block-file\"><object data-wp-bind--hidden=\"!state.hasPdfPreview\" hidden class=\"wp-block-file__embed\" data=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/06\/2026060400664_c.pdf\" type=\"application\/pdf\" style=\"width:100%;height:600px\" aria-label=\"Embed of 2026060400664_c.\"><\/object><a id=\"wp-block-file--media-de670425-a20c-42da-9b18-2d3f2176dccc\" href=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/06\/2026060400664_c.pdf\">2026060400664_c<\/a><a href=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/06\/2026060400664_c.pdf\" class=\"wp-block-file__button wp-element-button\" download aria-describedby=\"wp-block-file--media-de670425-a20c-42da-9b18-2d3f2176dccc\">Download<\/a><\/div>\n","protected":false},"excerpt":{"rendered":"<p>Innovent Biologics (HKG: 1801) announced that the pre-specified first interim analysis from the global Phase&#8230;<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,11],"tags":[35,16,910,198,38],"class_list":["post-67402","post","type-post","status-publish","format-standard","hentry","category-company","category-drug","tag-adc-xdc","tag-cancer","tag-hkg-1801","tag-innovent-biologics","tag-market-approval-filings"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v27.5 (Yoast SEO v27.7) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Innovent Biologics Reports Positive Phase III Results for IBI343 in Advanced Gastric Cancer \u2013 CLDN18.2-Targeting ADC Files NDA with NMPA - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Innovent Biologics (HKG: 1801) announced that the pre-specified first interim analysis from the global Phase III G-HOPE-001 study (NCT06238843) of IBI343 in patients with advanced gastric cancer has met its primary endpoint per protocol, demonstrating superior efficacy and a favorable safety and tolerability profile.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=67402\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Innovent Biologics Reports Positive Phase III Results for IBI343 in Advanced Gastric Cancer \u2013 CLDN18.2-Targeting ADC Files NDA with NMPA\" \/>\n<meta property=\"og:description\" content=\"Innovent Biologics (HKG: 1801) announced that the pre-specified first interim analysis from the global Phase III G-HOPE-001 study (NCT06238843) of IBI343 in patients with advanced gastric cancer has met its primary endpoint per protocol, demonstrating superior efficacy and a favorable safety and tolerability profile.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=67402\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2026-06-05T05:15:44+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-06-05T05:15:45+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2560\" \/>\n\t<meta property=\"og:image:height\" content=\"1894\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=67402#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=67402\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Innovent Biologics Reports Positive Phase III Results for IBI343 in Advanced Gastric Cancer \u2013 CLDN18.2-Targeting ADC Files NDA with NMPA\",\"datePublished\":\"2026-06-05T05:15:44+00:00\",\"dateModified\":\"2026-06-05T05:15:45+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=67402\"},\"wordCount\":381,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"keywords\":[\"ADC \\\/ XDC\",\"Cancer\",\"HKG: 1801\",\"Innovent Biologics\",\"Market approval filings\"],\"articleSection\":[\"Company\",\"Drug\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=67402#respond\"]}],\"copyrightYear\":\"2026\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=67402\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=67402\",\"name\":\"Innovent Biologics Reports Positive Phase III Results for IBI343 in Advanced Gastric Cancer \u2013 CLDN18.2-Targeting ADC Files NDA with NMPA - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"datePublished\":\"2026-06-05T05:15:44+00:00\",\"dateModified\":\"2026-06-05T05:15:45+00:00\",\"description\":\"Innovent Biologics (HKG: 1801) announced that the pre-specified first interim analysis from the global Phase III G-HOPE-001 study (NCT06238843) of IBI343 in patients with advanced gastric cancer has met its primary endpoint per protocol, demonstrating superior efficacy and a favorable safety and tolerability profile.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=67402#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=67402\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=67402#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Innovent Biologics Reports Positive Phase III Results for IBI343 in Advanced Gastric Cancer \u2013 CLDN18.2-Targeting ADC Files NDA with NMPA\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Innovent Biologics Reports Positive Phase III Results for IBI343 in Advanced Gastric Cancer \u2013 CLDN18.2-Targeting ADC Files NDA with NMPA - Insight, China&#039;s Pharmaceutical Industry","description":"Innovent Biologics (HKG: 1801) announced that the pre-specified first interim analysis from the global Phase III G-HOPE-001 study (NCT06238843) of IBI343 in patients with advanced gastric cancer has met its primary endpoint per protocol, demonstrating superior efficacy and a favorable safety and tolerability profile.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=67402","og_locale":"en_US","og_type":"article","og_title":"Innovent Biologics Reports Positive Phase III Results for IBI343 in Advanced Gastric Cancer \u2013 CLDN18.2-Targeting ADC Files NDA with NMPA","og_description":"Innovent Biologics (HKG: 1801) announced that the pre-specified first interim analysis from the global Phase III G-HOPE-001 study (NCT06238843) of IBI343 in patients with advanced gastric cancer has met its primary endpoint per protocol, demonstrating superior efficacy and a favorable safety and tolerability profile.","og_url":"https:\/\/flcube.com\/?p=67402","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2026-06-05T05:15:44+00:00","article_modified_time":"2026-06-05T05:15:45+00:00","og_image":[{"width":2560,"height":1894,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","type":"image\/jpeg"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=67402#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=67402"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Innovent Biologics Reports Positive Phase III Results for IBI343 in Advanced Gastric Cancer \u2013 CLDN18.2-Targeting ADC Files NDA with NMPA","datePublished":"2026-06-05T05:15:44+00:00","dateModified":"2026-06-05T05:15:45+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=67402"},"wordCount":381,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"keywords":["ADC \/ XDC","Cancer","HKG: 1801","Innovent Biologics","Market approval filings"],"articleSection":["Company","Drug"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=67402#respond"]}],"copyrightYear":"2026","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=67402","url":"https:\/\/flcube.com\/?p=67402","name":"Innovent Biologics Reports Positive Phase III Results for IBI343 in Advanced Gastric Cancer \u2013 CLDN18.2-Targeting ADC Files NDA with NMPA - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"datePublished":"2026-06-05T05:15:44+00:00","dateModified":"2026-06-05T05:15:45+00:00","description":"Innovent Biologics (HKG: 1801) announced that the pre-specified first interim analysis from the global Phase III G-HOPE-001 study (NCT06238843) of IBI343 in patients with advanced gastric cancer has met its primary endpoint per protocol, demonstrating superior efficacy and a favorable safety and tolerability profile.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=67402#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=67402"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=67402#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Innovent Biologics Reports Positive Phase III Results for IBI343 in Advanced Gastric Cancer \u2013 CLDN18.2-Targeting ADC Files NDA with NMPA"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/67402","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=67402"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/67402\/revisions"}],"predecessor-version":[{"id":67404,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/67402\/revisions\/67404"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=67402"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=67402"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=67402"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}